(Q38061006)

28 August 2017

1 reference

title

Resistant hypertension--its identification and epidemiology (English)

1 reference

28 August 2017

main subject

arterial hypertension

0 references

author name string

Pantelis A Sarafidis

series ordinal

1

1 reference

28 August 2017

Panagiotis Georgianos

series ordinal

2

1 reference

28 August 2017

George L Bakris

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

20 November 2012

1 reference

Nature Reviews Nephrology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

51-58

1 reference

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Predictors of new-onset kidney disease in a community-based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

The burden of blood pressure-related disease: a neglected priority for global health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Hypertension treatment and control in five European countries, Canada, and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Resistant hypertension: an overview of evaluation and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Epidemiology of resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

What is the prevalence of resistant hypertension in the United States?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Clinical practice. Resistant or difficult-to-control hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Mechanisms and treatment of resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Resistant hypertension revisited: a comparison of two university-based cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Refractory hypertension: definition, prevalence, and patient characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Hypertension awareness, treatment, and control in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Prevalence of resistant hypertension in the United States, 2003-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Incidence and prognosis of resistant hypertension in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Is resistant hypertension really resistant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

High prevalence of cardiac and extracardiac target organ damage in refractory hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Prognostic influence of office and ambulatory blood pressures in resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Differential Control of Systolic and Diastolic Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

31 March 2020

Resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Blood pressure and end-stage renal disease in men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Prognostic value of nocturnal blood pressure reduction in resistant hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.260

Resistant hypertension in a tertiary care clinic

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23165303

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23165303

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEPH.2012.260

1 reference

28 August 2017

1 reference